热门资讯> 正文
PainReform Confirms Optimal Delivery Method For PRF-110 In Bunionectomy Procedures Study
2024-08-21 20:34
PRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds
Findings Highlight PRF-110's Competitive Edge
Over Leading Pain Management Products
TEL AVIV, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful determination of the optimal delivery method for PRF-110 in bunionectomy procedures. This achievement marks a significant milestone aimed at advancing PRF-110 as a leading post-surgical pain management solution.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
